OMAHA, Neb., May 07, 2025 (GLOBE NEWSWIRE) -- On May 7, 2025, Greystone Housing Impact Investors LP (NYSE: GHI) (the “Partnership”) announced financial results for the three months ended March 31, 2025. Financial Highlights The Partnership reported the following results as of and for the three months ended March 31, 2025: Net income of $0.11 per Beneficial Unit Certificate (“BUC”), basic and dilutedCash Available for Distribution (“CAD”) of $0.31 per BUCTotal assets of $1.54 billionTotal Mortgage Revenue Bo ...

HORSHAM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report first quarter 2025 financial results on Wednesday, May 14, 2025 after the market close. STRATA management will subsequently host a conference call at 5:00 p.m. ET on Wednesday, May 14, 2025 to review financial res ...

Core Insights - Cellectar Biosciences, Inc. will report its financial results for Q1 2025 and provide a corporate update on May 13, 2025, at 8:30 a.m. Eastern Time [1] Company Overview - Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on discovering and developing proprietary drugs for cancer treatment, utilizing its Phospholipid Drug Conjugate™ (PDC) delivery platform to enhance efficacy and safety [3] Product Pipeline - The company's product pipeline includes lead assets such as iopofosine I 131, CLR 225, and CLR 125, targeting various solid tumors and leveraging advanced drug delivery technologies [4] - Iopofosine I 131 is currently in Phase 2b trials for relapsed or refractory multiple myeloma and CNS lymphoma, and is eligible for a Pediatric Review Voucher from the FDA [5] Regulatory Designations - Iopofosine I 131 has received multiple designations from the FDA, including six Orphan Drug, four Rare Pediatric Drug, and two Fast Track designations, as well as two Orphan Drug designations and PRIME designation from the EMA [5]

Core Insights - VivoSim Labs, Inc. announced the successful presentation of its NAMkind™ platform for liver toxicology prediction at the Digestive Disease Week Conference, showcasing its leading predictive capabilities in the industry [1][2] Company Overview - VivoSim's NAMkind™ liver model achieved a sensitivity of 87.5% in identifying liver-toxic drugs, with a specificity of 100%, indicating no false positives among non-toxic compounds [2] - The platform utilizes a physical organoid wet lab model made from human donor cells and is developing advanced in silico predictions using AI trained on proprietary data [3] Market Context - The FDA's initiative to phase out animal testing in favor of non-animal methods is expected to significantly boost the adoption of VivoSim's NAM models, which could disrupt a market exceeding $10 billion [4][7] - VivoSim aims to reduce clinical trial failures and associated costs by 50% through improved predictions of liver toxicity, addressing a critical issue in drug development [5] Product Capabilities - The NAMkind™ intestine models are designed to provide insights on endpoints currently unavailable to researchers, potentially improving patient outcomes during chemotherapy [6] - The company is positioned to fill the gap in commercially available solutions as the FDA moves towards NAM models, leveraging AI and human organ models for safer and more efficient drug development [7]

The CARTIHEAL Implant will be featured at the Arthroscopy Association of North America Annual Meeting (AANA 2025) this week Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces encouraging results for its CARTIHEAL AGILI-C Cartilage Repair Implant from a recent multicentre randomised controlled trial (RCT) treating knee cartilage defects. When compared to the current surgical standard of care,* the implant demonstrated: Superior pain relief: Patients treated with the CART ...

WESTON, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA), a clinical-stage biopharmaceutical company specializing in first-in-class therapies for inflammatory and renal diseases, announces significant developments for Inflammasome ASC Inhibitor IC 100. CEO Stephen C. Glover issued a shareholder letter detailing the company's strategy to position IC 100 as a complementary therapy to GLP-1 agonists to treat obesity-associated cardiometabolic complications. Obesity: A Global Hea ...

MONACO , May 07, 2025 (GLOBE NEWSWIRE) -- Costamare Inc. (NYSE:CMRE) (the “Company”) announced today that it has completed the spin-off of its dry bulk business into a standalone public company, Costamare Bulkers Holdings Limited (“Costamare Bulkers”). Each holder of Costamare Inc. common shares received one common share of Costamare Bulkers Holdings Limited for every five Costamare Inc. common shares held as of the close of business on April 29, 2025. The successful execution of the Costamare Bulkers spin- ...

Company completes separation from Costamare Inc.Begins trading today on NYSE MONACO, May 07, 2025 (GLOBE NEWSWIRE) -- Costamare Bulkers Holdings Limited (NYSE:CMDB) (“Costamare Bulkers” or the “Company”) announced today its debut as an independent, publicly traded company and the completion of its separation from Costamare Inc. The Company’s shares begin trading today from 9:30 a.m., New York City time on the New York Stock Exchange (the “NYSE”) under the symbol “CMDB.” Costamare Inc. will continue to trade ...

First quarter 2025 GAAP net income of $3.1 million or $0.27 per basic weighted average common share and Distributable Earnings(1) of $3.5 million or $0.31 per basic weighted average common shareWEST PALM BEACH, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- Sunrise Realty Trust, Inc. (NASDAQ:SUNS) (“SUNS” or the “Company”) today announced its results for the quarter ended March 31, 2025. SUNS reported generally accepted accounting principles (“GAAP”) net income of $3.1 million or $0.27 per basic weighted average co ...

Announces successful completion of sub-chronic and chronic toxicology studies for INF904, supporting long-term dosing in future clinical trialsMultiple near-term catalysts anticipated with the potential to substantially de-risk the Company's pipeline addressing multiple sizable marketsInterim analysis for vilobelimab Phase 3 trial in pyoderma gangrenosum (PG), to determine trial size adaptation or futility, remains on schedule with a recommendation expected to be announced at the end of May to early JuneTop ...